Colorectal Cancer - Pipeline Review, H2 2016

 

Rating

4.9 Star Rating for report Colorectal Cancer - Pipeline Review, H2 2016
4.9 / 5 stars rating
Pages: 1645
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2016, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-28 

Report: Colorectal Cancer - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 12
Colorectal Cancer Overview 13
Therapeutics Development 14
Colorectal Cancer - Therapeutics under Development by Companies 16
Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 36
Colorectal Cancer - Pipeline Products Glance 38
Colorectal Cancer - Products under Development by Companies 42
Colorectal Cancer - Products under Investigation by Universities/Institutes 71
Colorectal Cancer - Companies Involved in Therapeutics Development 74
Colorectal Cancer - Therapeutics Assessment 312
Drug Profiles 359
Colorectal Cancer - Dormant Projects 1545
Colorectal Cancer - Discontinued Products 1576
Colorectal Cancer - Product Development Milestones 1584
Appendix 1593
 

List of Tables

List of Tables
Number of Products under Development for Colorectal Cancer, H2 2016 65
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2016 66
Number of Products under Development by Companies, H2 2016 68
Number of Products under Development by Companies, H2 2016 (Contd..1) 69
Number of Products under Development by Companies, H2 2016 (Contd..2) 70
Number of Products under Development by Companies, H2 2016 (Contd..3) 71
Number of Products under Development by Companies, H2 2016 (Contd..4) 72
Number of Products under Development by Companies, H2 2016 (Contd..5) 73
Number of Products under Development by Companies, H2 2016 (Contd..6) 74
Number of Products under Development by Companies, H2 2016 (Contd..7) 75
Number of Products under Development by Companies, H2 2016 (Contd..8) 76
Number of Products under Development by Companies, H2 2016 (Contd..9) 77
Number of Products under Development by Companies, H2 2016 (Contd..10) 78
Number of Products under Development by Companies, H2 2016 (Contd..11) 79
Number of Products under Development by Companies, H2 2016 (Contd..12) 80
Number of Products under Development by Companies, H2 2016 (Contd..13) 81
Number of Products under Development by Companies, H2 2016 (Contd..14) 82
Number of Products under Development by Companies, H2 2016 (Contd..15) 83
Number of Products under Development by Companies, H2 2016 (Contd..16) 84
Number of Products under Development by Companies, H2 2016 (Contd..17) 85
Number of Products under Development by Companies, H2 2016 (Contd..18) 86
Number of Products under Investigation by Universities/Institutes, H2 2016 87
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 88
Comparative Analysis by Late Stage Development, H2 2016 89
Comparative Analysis by Clinical Stage Development, H2 2016 90
Comparative Analysis by Early Stage Development, H2 2016 91
Comparative Analysis by Unknown Stage Development, H2 2016 92
Products under Development by Companies, H2 2016 93
Products under Development by Companies, H2 2016 (Contd..1) 94
Products under Development by Companies, H2 2016 (Contd..2) 95
Products under Development by Companies, H2 2016 (Contd..3) 96
Products under Development by Companies, H2 2016 (Contd..4) 97
Products under Development by Companies, H2 2016 (Contd..5) 98
Products under Development by Companies, H2 2016 (Contd..6) 99
Products under Development by Companies, H2 2016 (Contd..7) 100
Products under Development by Companies, H2 2016 (Contd..8) 101
Products under Development by Companies, H2 2016 (Contd..9) 102
Products under Development by Companies, H2 2016 (Contd..10) 103
Products under Development by Companies, H2 2016 (Contd..11) 104
Products under Development by Companies, H2 2016 (Contd..12) 105
Products under Development by Companies, H2 2016 (Contd..13) 106
Products under Development by Companies, H2 2016 (Contd..14) 107
Products under Development by Companies, H2 2016 (Contd..15) 108
Products under Development by Companies, H2 2016 (Contd..16) 109
Products under Development by Companies, H2 2016 (Contd..17) 110
Products under Development by Companies, H2 2016 (Contd..18) 111
Products under Development by Companies, H2 2016 (Contd..19) 112
Products under Development by Companies, H2 2016 (Contd..20) 113
Products under Development by Companies, H2 2016 (Contd..21) 114
Products under Development by Companies, H2 2016 (Contd..22) 115
Products under Development by Companies, H2 2016 (Contd..23) 116
Products under Development by Companies, H2 2016 (Contd..24) 117
Products under Development by Companies, H2 2016 (Contd..25) 118
Products under Development by Companies, H2 2016 (Contd..26) 119
Products under Development by Companies, H2 2016 (Contd..27) 120
Products under Development by Companies, H2 2016 (Contd..28) 121
Products under Investigation by Universities/Institutes, H2 2016 122
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 123
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 124
Colorectal Cancer - Pipeline by 2cureX ApS, H2 2016 125
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 126
Colorectal Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016 127
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2016 128
Colorectal Cancer - Pipeline by 4SC AG, H2 2016 129
Colorectal Cancer - Pipeline by AB Science SA, H2 2016 130
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2016 131
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2016 132
Colorectal Cancer - Pipeline by Accelerated Pharma Inc, H2 2016 133
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2016 134
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2016 135
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 136
Colorectal Cancer - Pipeline by Alchemia Ltd, H2 2016 137
Colorectal Cancer - Pipeline by Allinky Biopharma, H2 2016 138
Colorectal Cancer - Pipeline by Amal Therapeutics SA, H2 2016 139
Colorectal Cancer - Pipeline by amcure GmbH, H2 2016 140
Colorectal Cancer - Pipeline by Amgen Inc, H2 2016 141
Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H2 2016 142
Colorectal Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 143
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2016 144
Colorectal Cancer - Pipeline by Aphios Corp, H2 2016 145
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2016 146
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 147
Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 148
Colorectal Cancer - Pipeline by ArQule Inc, H2 2016 149
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2016 150
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2016 151
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 152
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2016 153
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 154
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2016 155
Colorectal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 156
Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 157
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2016 158
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 159
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 160
Colorectal Cancer - Pipeline by Bayer AG, H2 2016 161
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2016 162
Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 163
Colorectal Cancer - Pipeline by Biocon Ltd, H2 2016 164
Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2016 165
Colorectal Cancer - Pipeline by Bionovis SA, H2 2016 166
Colorectal Cancer - Pipeline by Biotecnol Ltd, H2 2016 167
Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016 168
Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 169
Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2016 170
Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 171
Colorectal Cancer - Pipeline by Burzynski Research Institute Inc, H2 2016 172
Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 173
Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2016 174
Colorectal Cancer - Pipeline by Carna Biosciences Inc, H2 2016 175
Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 176
Colorectal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016 177
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2016 178
Colorectal Cancer - Pipeline by Celgene Corp, H2 2016 179
Colorectal Cancer - Pipeline by Cellceutix Corp, H2 2016 180
Colorectal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 181
Colorectal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 182
Colorectal Cancer - Pipeline by Celltrion Inc, H2 2016 183
Colorectal Cancer - Pipeline by Celyad SA, H2 2016 184
Colorectal Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 185
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 186
Colorectal Cancer - Pipeline by ChoDang Pharm Co Ltd, H2 2016 187
Colorectal Cancer - Pipeline by Cipla Ltd, H2 2016 188
Colorectal Cancer - Pipeline by Cleave Biosciences Inc, H2 2016 189
Colorectal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2016 190
Colorectal Cancer - Pipeline by COARE Biotechnology Inc, H2 2016 191
Colorectal Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 192
Colorectal Cancer - Pipeline by Compugen Ltd, H2 2016 193
Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 194
Colorectal Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 195
Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 196
Colorectal Cancer - Pipeline by CrystalGenomics Inc, H2 2016 197
Colorectal Cancer - Pipeline by Cytune Pharma SAS, H2 2016 198
Colorectal Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 199
Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H2 2016 200
Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 201
Colorectal Cancer - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 202
Colorectal Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016 203
Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 204
Colorectal Cancer - Pipeline by EirGenix Inc, H2 2016 205
Colorectal Cancer - Pipeline by Eisai Co Ltd, H2 2016 206
Colorectal Cancer - Pipeline by Eli Lilly and Company, H2 2016 207
Colorectal Cancer - Pipeline by Endor Nanotechnologies SL, H2 2016 208
Colorectal Cancer - Pipeline by enGene Inc, H2 2016 209
Colorectal Cancer - Pipeline by EnGeneIC Ltd, H2 2016 210
Colorectal Cancer - Pipeline by Ensol Biosciences Inc, H2 2016 211
Colorectal Cancer - Pipeline by EntreChem SL, H2 2016 212
Colorectal Cancer - Pipeline by Enzo Biochem Inc, H2 2016 213
Colorectal Cancer - Pipeline by Etubics Corp, H2 2016 214
Colorectal Cancer - Pipeline by Exelixis Inc, H2 2016 215
Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 216
Colorectal Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2016 217
Colorectal Cancer - Pipeline by Formosa Laboratories Inc, H2 2016 218
Colorectal Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016 220
Colorectal Cancer - Pipeline by Genentech Inc, H2 2016 221
Colorectal Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016 222
Colorectal Cancer - Pipeline by Genoscience Pharma, H2 2016 223
Colorectal Cancer - Pipeline by Genzyme Corp, H2 2016 224
Colorectal Cancer - Pipeline by Gilead Sciences Inc, H2 2016 225
Colorectal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 226
Colorectal Cancer - Pipeline by Glycotope GmbH, H2 2016 227
Colorectal Cancer - Pipeline by Golden Biotechnology Corp, H2 2016 228
Colorectal Cancer - Pipeline by Green Cross Corp, H2 2016 229
Colorectal Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 230
Colorectal Cancer - Pipeline by Handok Inc, H2 2016 231
Colorectal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 232
Colorectal Cancer - Pipeline by Heat Biologics Inc, H2 2016 233
Colorectal Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016 234
Colorectal Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016 235
Colorectal Cancer - Pipeline by iDD biotech SAS, H2 2016 236
Colorectal Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016 237
Colorectal Cancer - Pipeline by Ignyta Inc, H2 2016 238
Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd, H2 2016 239
Colorectal Cancer - Pipeline by ImmuneXcite Inc, H2 2016 240
Colorectal Cancer - Pipeline by Immunomedics Inc, H2 2016 241
Colorectal Cancer - Pipeline by Immunovative Therapies Ltd, H2 2016 242
Colorectal Cancer - Pipeline by Incanthera Ltd, H2 2016 243
Colorectal Cancer - Pipeline by Incyte Corp, H2 2016 244
Colorectal Cancer - Pipeline by Innovent Biologics Inc, H2 2016 245
Colorectal Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 246
Colorectal Cancer - Pipeline by Interprotein Corp, H2 2016 247
Colorectal Cancer - Pipeline by Intezyne Technologies Inc, H2 2016 248
Colorectal Cancer - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 249
Colorectal Cancer - Pipeline by IPD Therapeutics BV, H2 2016 250
Colorectal Cancer - Pipeline by Isofol Medical AB, H2 2016 251
Colorectal Cancer - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 252
Colorectal Cancer - Pipeline by JHL Biotech Inc, H2 2016 253
Colorectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2016 254
Colorectal Cancer - Pipeline by Johnson & Johnson, H2 2016 255
Colorectal Cancer - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 256
Colorectal Cancer - Pipeline by Kancera AB, H2 2016 257
Colorectal Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2016 258
Colorectal Cancer - Pipeline by Kura Oncology Inc, H2 2016 259
Colorectal Cancer - Pipeline by Laboratorio ELEA SACIF y A, H2 2016 260
Colorectal Cancer - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016 261
Colorectal Cancer - Pipeline by Lion Biotechnologies Inc, H2 2016 262
Colorectal Cancer - Pipeline by LipoMedix Pharmaceutical Inc, H2 2016 263
Colorectal Cancer - Pipeline by Loxo Oncology, Inc., H2 2016 264
Colorectal Cancer - Pipeline by Mabion SA, H2 2016 265
Colorectal Cancer - Pipeline by Mabtech Ltd, H2 2016 266
Colorectal Cancer - Pipeline by mAbxience SA, H2 2016 267
Colorectal Cancer - Pipeline by MacroGenics Inc, H2 2016 268
Colorectal Cancer - Pipeline by Marina Biotech Inc, H2 2016 269
Colorectal Cancer - Pipeline by MediaPharma srl, H2 2016 270
Colorectal Cancer - Pipeline by MedImmune LLC, H2 2016 271
Colorectal Cancer - Pipeline by Medinet Co Ltd, H2 2016 272
Colorectal Cancer - Pipeline by Merck & Co Inc, H2 2016 273
Colorectal Cancer - Pipeline by Merck KGaA, H2 2016 274
Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 275
Colorectal Cancer - Pipeline by Merus NV, H2 2016 276
Colorectal Cancer - Pipeline by Microlin Bio, Inc., H2 2016 277
Colorectal Cancer - Pipeline by MolMed SpA, H2 2016 278
Colorectal Cancer - Pipeline by Mologen AG, H2 2016 279
Colorectal Cancer - Pipeline by Morphotek Inc, H2 2016 280
Colorectal Cancer - Pipeline by Multimmune GmbH, H2 2016 281
Colorectal Cancer - Pipeline by Mycenax Biotech Inc, H2 2016 282
Colorectal Cancer - Pipeline by Natco Pharma Ltd, H2 2016 283
Colorectal Cancer - Pipeline by NatureWise Biotech & Medicals Corp, H2 2016 284
Colorectal Cancer - Pipeline by Nektar Therapeutics, H2 2016 285
Colorectal Cancer - Pipeline by Neovacs SA, H2 2016 286
Colorectal Cancer - Pipeline by Nerviano Medical Sciences Srl, H2 2016 287
Colorectal Cancer - Pipeline by Nippon Kayaku Co Ltd, H2 2016 288
Colorectal Cancer - Pipeline by NormOxys Inc, H2 2016 289
Colorectal Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2016 290
Colorectal Cancer - Pipeline by Novartis AG, H2 2016 291
Colorectal Cancer - Pipeline by Novogen Ltd, H2 2016 292
Colorectal Cancer - Pipeline by Noxxon Pharma AG, H2 2016 293
Colorectal Cancer - Pipeline by NuCana BioMed Ltd, H2 2016 294
Colorectal Cancer - Pipeline by OBI Pharma Inc, H2 2016 295
Colorectal Cancer - Pipeline by Oncobiologics Inc, H2 2016 296
Colorectal Cancer - Pipeline by Oncolytics Biotech Inc, H2 2016 297
Colorectal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 298
Colorectal Cancer - Pipeline by Onconova Therapeutics Inc, H2 2016 299
Colorectal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 300
 

List of Figures

List of Figures
Number of Products under Development for Colorectal Cancer, H2 2016 65
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H2 2016 66
Number of Products under Development by Companies, H2 2016 67
Number of Products under Investigation by Universities/Institutes, H2 2016 87
Comparative Analysis by Late Stage Development, H2 2016 89
Comparative Analysis by Clinical Stage Development, H2 2016 90
Comparative Analysis by Early Stage Products, H2 2016 91
Assessment by Monotherapy Products, H2 2016 363
Assessment by Combination Products, H2 2016 364
Number of Products by Top 10 Targets, H2 2016 365
Number of Products by Stage and Top 10 Targets, H2 2016 365
Number of Products by Top 10 Mechanism of Actions, H2 2016 385
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 385
Number of Products by Top 10 Routes of Administration, H2 2016 406
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 406
Number of Products by Top 10 Molecule Types, H2 2016 408
Number of Products by Stage and Top 10 Molecule Types, H2 2016 408
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 26, 106, 110, 9, 145, 36 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 15, 8, 22 and 3 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 1645 

Companies Featured

2cureX ApS 3-V Biosciences Inc 3M Drug Delivery Systems 3SBio Inc 4SC AG AB Science SA AbbVie Inc AbGenomics International Inc Accelerated Pharma Inc Adamed Sp z oo Aduro BioTech Inc Advenchen Laboratories LLC Alchemia Ltd Allinky Biopharma Amal Therapeutics SA amcure GmbH Amgen Inc Antibe Therapeutics Inc Apac Biotech Pvt Ltd Apexigen Inc Aphios Corp Aposense Ltd Arisaph Pharmaceuticals Inc ARMO Biosciences Inc ArQule Inc Array BioPharma Inc Asana BioSciences LLC Aslan Pharmaceuticals Pte Ltd Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc ATLAB Pharma SAS AVEO Pharmaceuticals Inc B Cell Design SAS Basilea Pharmaceutica Ltd Bavarian Nordic A/S Bayer AG BeiGene Ltd BeyondSpring Pharmaceuticals Inc Biocon Ltd Bionomics Ltd Bionovis SA Biotecnol Ltd Biothera Pharmaceutical Inc Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Burzynski Research Institute Inc Calithera Biosciences Inc Cancer Prevention Pharmaceuticals Inc Carna Biosciences Inc Cascadian Therapeutics Inc CBT Pharmaceuticals Inc CCRP Therapeutics GmbH Celgene Corp Cellceutix Corp Celldex Therapeutics Inc Cellectar Biosciences Inc Celltrion Inc Celyad SA Chiome Bioscience Inc Chipscreen Biosciences Ltd ChoDang Pharm Co Ltd Cipla Ltd Cleave Biosciences Inc Cleveland BioLabs Inc COARE Biotechnology Inc Coherus BioSciences Inc Compugen Ltd Cornerstone Pharmaceuticals Inc Corvus Pharmaceuticals Inc Critical Outcome Technologies Inc CrystalGenomics Inc Cytune Pharma SAS Daiichi Sankyo Company Ltd DanDrit Biotech A/S Deciphera Pharmaceuticals LLC Dicerna Pharmaceuticals Inc Double Bond Pharmaceutical International AB Dr. Reddy's Laboratories Ltd EirGenix Inc Eisai Co Ltd Eli Lilly and Company Endor Nanotechnologies SL enGene Inc EnGeneIC Ltd Ensol Biosciences Inc EntreChem SL Enzo Biochem Inc Etubics Corp Exelixis Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Formosa Laboratories Inc Fusion Antibodies Ltd Gene Techno Science Co Ltd Genentech Inc Genor BioPharma Co Ltd Genoscience Pharma Genzyme Corp Gilead Sciences Inc GlaxoSmithKline Plc Glycotope GmbH Golden Biotechnology Corp Green Cross Corp Hadasit Medical Research Services & Development Ltd Handok Inc Hanmi Pharmaceuticals Co Ltd Heat Biologics Inc Hemispherx Biopharma Inc Hutchison MediPharma Ltd iDD biotech SAS Ideaya Biosciences Inc Ignyta Inc Immodulon Therapeutics Ltd ImmuneXcite Inc Immunomedics Inc Immunovative Therapies Ltd Incanthera Ltd Incyte Corp Innovent Biologics Inc Inovio Pharmaceuticals Inc Interprotein Corp Intezyne Technologies Inc Ionis Pharmaceuticals Inc IPD Therapeutics BV Isofol Medical AB Jeil Pharmaceutical Co Ltd JHL Biotech Inc Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson KaloBios Pharmaceuticals Inc Kancera AB Karyopharm Therapeutics Inc Kura Oncology Inc Laboratorio ELEA SACIF y A Lee's Pharmaceutical Holdings Ltd Lion Biotechnologies Inc LipoMedix Pharmaceutical Inc Loxo Oncology, Inc. Mabion SA Mabtech Ltd mAbxience SA MacroGenics Inc Marina Biotech Inc MediaPharma srl MedImmune LLC Medinet Co Ltd Merck & Co Inc Merck KGaA Merrimack Pharmaceuticals Inc Merus NV Microlin Bio, Inc. MolMed SpA Mologen AG Morphotek Inc Multimmune GmbH Mycenax Biotech Inc Natco Pharma Ltd NatureWise Biotech & Medicals Corp Nektar Therapeutics Neovacs SA Nerviano Medical Sciences Srl Nippon Kayaku Co Ltd NormOxys Inc Northwest Biotherapeutics Inc Novartis AG Novogen Ltd Noxxon Pharma AG NuCana BioMed Ltd OBI Pharma Inc Oncobiologics Inc Oncolytics Biotech Inc OncoMed Pharmaceuticals Inc Onconova Therapeutics Inc Ono Pharmaceutical Co Ltd Oryx GmbH & Co KG Otsuka Holdings Co Ltd Oxford BioMedica Plc Pfizer Inc Pharma Mar SA PharmAbcine Inc Pivot Pharmaceuticals Inc Pivotal BioSciences Inc PlantForm Corp PLx Pharma Inc Precision Biologics Inc Prima BioMed Ltd Propanc Health Group Corp Provectus Biopharmaceuticals Inc PsiOxus Therapeutics Ltd Puma Biotechnology Inc R Pharm RedHill Biopharma Ltd Redx Pharma Plc Regeneron Pharmaceuticals Inc Rexahn Pharmaceuticals Inc Rgenix Inc Rhizen Pharmaceuticals SA Richter Gedeon Nyrt Samumed LLC Sanofi Selvita SA Shanghai Henlius Biotech Co Ltd Shire Plc Sigma-Tau SpA Sigmoid Pharma Ltd Sillajen Biotherapeutics Solvotrin Therapeutics Ltd Sorrento Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd SuviCa Inc Symphogen A/S Synermore Biologics Co Ltd Taiho Pharmaceutical Co Ltd TaiwanJ Pharmaceuticals Co Ltd Takeda Pharmaceutical Company Ltd Tara Immuno-Oncology Therapeutics LLC Targovax ASA Tarveda Therapeutics Inc Theravectys SA Tiltan Pharma Ltd Tocagen Inc TRACON Pharmaceuticals Inc Transgene SA TyrNovo Ltd United BioPharma Inc Vaccinex Inc VasGene Therapeutics Inc Vaximm AG Verastem Inc Vertex Pharmaceuticals Inc Viralytics Ltd Wilex AG WntResearch AB XBiotech Inc XuanZhu Pharma Co Ltd Zymeworks Inc

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8864IDBNon-Small Cell Lung Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8866IDBOvarian Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8868IDBMelanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8869IDBAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - P...Dec 2016
Report... 05IB-GMDHC8871IDBBreast Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8860IDBProstate Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8844IDBMultiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8816IDBKidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016Dec 2016

Colorectal Cancer - Pipeline Review, H2 2016

Report 05IB-GMDHC8870IDB has a rating of 95.6 percent
Figure of merit assessment for report 05IB-GMDHC8870IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Colorectal Cancer - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8870IDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [2.91727s]

--